Evercore ISI initiated coverage of ProQR Therapeutics (PRQR) with an Outperform rating and $5 price target ProQR represents a “true” biotech investment given its early-stage, emerging technology with “a plethora of potential applications,” ovel first in class targets and a wide array of strategic optionality for the company, but over the last few years investors have increasingly focused on derisked targets and indications, which is why the stock is trading at cash despite what the firm calls “significant internal progress” and external validation.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRQR:
- ProQR Announces New CFO and CMO to Drive Growth
- ProQR Therapeutics appoints Hom as CFO, Lopez as CMO
- ProQR Therapeutics Advances RNA Editing Pipeline
- ProQR’s Axiomer Technology and AX-0810: A Promising Buy Rating with Increased Price Target
- ProQR Therapeutics price target raised to $12 from $10 at H.C. Wainwright